



Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease

Nadežda Pupina,^a Annela Avarlaid,^b Helle Sadam,^{a,b} Arno Pihlak,^a Mariliis Jaago,^{a,b} Jürgen Tuvikene,^{a,b,c} Annika Rähni,^{a,b} Anu Planken,^d Margus Planken,^d Eija Kalso,^e Pentti J. Tienari,^f Janne K. Nieminen,^f Mikko R.J. Seppänen,^f Antti Vaheri,^g Dan Lindholm,^{h,i} Juha Sinisalo,^j Pirkko Pussinen,^k Tõnis Timmusk,^{a,b} and Kaia Palm^{a,b*}

^aProtobios LLC, Mäealuse 4, Tallinn 12618, Estonia

^bDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Estonia

^cdxlabs LLC, Mäealuse 4, Tallinn 12618, Estonia

^dThe North Estonia Medical Center, Tallinn, Estonia

^eDepartment of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and Department of Pharmacology and SleepWell Research Programme, University of Helsinki, Finland

^fDepartment of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Finland

^gDepartment of Virology, Medicum, University of Helsinki, Finland

^hDepartment of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Finland

ⁱMinerva Foundation Institute for Medical Research, Helsinki, Finland

^jHeart and Lung Center, Helsinki University Hospital, University of Helsinki, Finland

^kOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Finland

Summary

Background Major cardiac events including myocardial infarction (MI) are associated with viral infections. However, how specific infections contribute to the cardiovascular insults has remained largely unclear.

Methods We employed next generation phage display mimotope-variation analysis (MVA) to explore the link between antibody-based immune response and severe cardiovascular conditions. Here, we used a case-control design, including the first-stage discovery cohort ($n = 100$), along with cohorts for second-stage discovery ($n = 329$) and validation ($n = 466$).

Findings We observed strong antibody response to the peptide antigens with Gly-Ile-X-Asp (G-I-X-D) core structure in healthy individuals but not in patients with MI. Analysis of the origin of this epitope linked it with the N-terminus of the VP1 protein of poliovirus 3 (PV3), but also other species of picornaviruses. Consistently, we found low levels of antibody response to the G-I-X-D epitope in individuals with severe cardiac disease complications.

Interpretation Our findings imply that antibody response to the G-I-X-D epitope is associated with polio vaccinations and that high antibody levels to this epitope could discriminate healthy individuals from prospective MI patients as a blood-derived biomarker. Together, these findings highlight the importance of epitope-specific antibody response and suggest that protective immunity against the polio- and non-polio enteroviral infections support improved cardiovascular health.

Funding Estonian Ministry of Education (5.1-4/20/170), Estonian Research Council (PRG573, PRG805), H2020-MSCA-RISE-2016 (EU734791), H2020 PANBioRA (EU760921), European Union through the European Regional Development Fund (Project no. 2014-2020.4.01.15-0012), Helsinki University Hospital grants, Mary and Georg C. Ehrnrooth Foundation, Finnish Eye Foundation, Finska Läkaresällskapet, The Finnish Society of Sciences and Letters, Magnus Ehrnrooth Foundation and Sigrid Jusélius Foundation.

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Keywords: Epitope; Antibodies; Myocardial infarction; Cardiovascular diseases; Poliovirus; Enteroviruses

*Corresponding author at: Protobios LLC, Mäealuse 4, Tallinn 12618, Estonia.

E-mail address: kaia@protobios.com (K. Palm).

Research in context

Evidence before this study

Cardiovascular diseases (CVDs) are the leading cause of death globally. High blood pressure, smoking, high cholesterol levels, obesity, and diabetes are among the major risk factors contributing to CVD development.

Added value of this study

Here, we used high-throughput analysis of the antibody immune response in search of novel CVD-associated biomarkers and found value in measuring the immunoreactivity to a single viral epitope as a blood-based biomarker for the risk assessment of the CVD associated acute cardiac events.

Implications of all the available evidence

The understanding of novel viral infection-associated mechanisms along with noninvasive cardiac-specific biomarkers may yield valuable insights into the CVD pathophysiology and prevention at an early stage of the disease. Given that we relate this epitope to cross-protective poliovirus antigens, the study data would contribute to further vaccine use and improvements.

Introduction

Cardiovascular diseases (CVDs) are the leading global burden with coronary artery disease (CAD) as a major contributor to the fatalities, and myocardial infarction (MI) accounting for most of the mortality.^{1,2}

External stress factors that have detrimental impact on the integrity of the cellular machinery promote the development of cardiac disorders.³ CAD is the most common heart problem that involves the blood vessels and usually starts as a result of atherosclerosis and may culminate in MI, a major adverse cardiovascular event.⁴ In the atherosclerotic disease process, the role of inflammation has become well established.^{5,6} Considerable evidence has emerged indicating that infections contribute to chronic inflammation either through direct effects by hijacking cellular processes and inducing host inflammatory cascades, or indirectly via an autoimmune-mediated response, or a combination of both.⁷

Infectious diseases of the heart are heterogeneous. They have variable clinical presentations as any type of microorganism, e.g. bacteria, fungi, parasites, and viruses, may affect more than one cardiac structure.⁸ A number of acute and chronic infections including *Chlamydia pneumoniae*, *Helicobacter pylori*, *Porphyromonas gingivalis*, influenza and coronaviruses, e.g. SARS-CoV-2^{9,10} has been linked to atherosclerosis¹¹ and MI.¹² In both cross-sectional and cohort studies, elevated antibodies against *C. pneumoniae*, *H. pylori*, periodontal pathogens, *Mycoplasma pneumoniae*, herpes viruses, and enteroviruses have been demonstrated.^{13–16} Further,

data suggest that the general infectious burden poses a greater risk for coronary heart disease (CHD) than any single pathogen.^{17–19} A unique study by Pesonen and co-workers showed that the antibody titers against pathogens like enteroviruses cumulatively increased the risk for CHD, whereas the risk for acute coronary events decreased with increasing number of childhood contagious diseases.²⁰ On the other hand, childhood oral infections and infection-related hospitalisations were associated with subclinical carotid atherosclerosis and adverse atherosclerosis phenotype in adults.^{21,22} Increased risk for acute coronary syndrome (ACS) was found for acute bacterial pneumonia, urinary tract infection and bacteremia with different bacterial strains.²³

Excess mortality from cardiovascular disease during influenza epidemics was recognised early in the 20th century, and recent reports indicate that COVID-19 may also be associated with a similar increase.²³ There is no direct evidence that viral vaccines would have an influence on atherosclerosis in humans.²⁴ However, studies showed that influenza and pneumococcal vaccination reduce the risk for cardiovascular events in adults by 36%²⁵ and 17%,²⁶ respectively. The molecular mechanisms by which vaccinations exert these protective effects have not been defined.

The current study investigated the relationship between antibody immune response associated with MI by using an untargeted, high-throughput next generation peptide phage display method (MVA). We have correlated these results with the data from the case-control cohort comprising of patients with angiographically verified CVDs status, i.e. ACS and chronic CAD, and population-based controls to evaluate associations of antibody immune response as a predictive blood biomarker for CVD conditions.

Methods

Ethics statement

The study was conducted in accordance with the guiding principles of the Declaration of 182 Helsinki and the study participants gave written informed consent before enrolment. The ethical approvals were obtained from the local ethics review committees of Estonia (177/T-2, 211/M-22, 281/T-5; 351), and Finland (the Helsinki University Central Hospital ethics committee (106/2007, 303/2007); Helsinki University Hospital (Dno 83/13/03/01/2013); Helsinki Biobank (HBP2018006)). Healthy sera donor samples were procured from the North Estonia Medical Blood Centre (Tallinn, Estonia).

Study populations

The summary of the study design is illustrated in Figure S1. Baseline characteristics for the cohorts used are shown in Tables 1 and S1, S3 and S4. In brief, study was

	Healthy control (HC)	Myocardial infarction (MI)
Group size (n)	50	50
Gender	20 M; 30F	29 M; 13 F; 8 NA
Mean age \pm SD (min-max), years	40.76 \pm 9.86 (21–58)	66.78 \pm 12.58 (38–88)*; 10 NA

Table 1: Characterisation of the Estonia I cohort (Figure S1).
The age of the individuals was fixed at the time of sample collection. HC – healthy control; MI – myocardial infarction patients; M – male; F – female; NA – not available; patient agreeing to the study did not disclose the exact age or gender.
* – data on 40 subjects.

designed as 2-stage case-control study including three cohorts, Estonia I and II, and Finland I. Using a case-control design, the first-stage discovery cohort (Estonia I, $n = 100$) was built from the samples collected by North Estonian Regional Hospital (Tallinn, Estonia) including serum or plasma of MI ($n = 50$) and HC ($n = 50$). MI was diagnosed according to electrocardiogram and cardiac marker analysis (troponin, creatine kinase-MB). The case condition included ST-elevation (STEMI) and non-ST-elevation (NSTEMI) myocardial infarction patients. All MI samples were collected less than 12 h before or after the coronary angiography procedures and stored at -80°C until further use. Heart conditions were excluded for the HC group. In the second stage of the study, we were aiming to associate the discovered epitope with different types of poliovirus vaccines. Another discovery cohort Estonia II ($n = 329$) was created by combining samples of previous retrospective studies from (a) subjects born in years 1927–1958 ($n = 101$, *No vaccine*), when no polio vaccine was available, also in Estonia, (b) subjects born in years of OPV vaccination according to the national immunisation history (years 1959–2007, $n = 224$, *OPV*), and (c) individuals born in years of IPV vaccination programmes in Estonia (years 2008–2011, $n = 4$, *IPV*) (Table S3). It should be mentioned that individuals from *No vaccine* group could have received OPV during mass vaccination programmes in 1959 and 1960 in their adulthood^{27,28} (Figure S2). Regarding clinical background, the Estonia II cohort consisted of MI cases ($n = 40$) and either healthy blood donors (ICD-10: Z52.0, $n = 135$) or samples from individuals with different primary diagnoses with no history of MI ($n = 154$) (including patients with cervical intraepithelial pathologies ($n = 42$), prediabetes ($n = 6$), psoriasis ($n = 31$), sarcoidosis ($n = 47$), allergies ($n = 4$), or individuals without any specified primary diagnosis ($n = 24$)) collected during physician appointments. The validation cohort Finland I ($n = 466$) was built to replicate the findings from Estonia I (Table S4). This cohort included the plasma samples of the Corogene study²⁹ to represent subjects with CAD/ACS (CVD, $n = 64$). The CVD group included samples from patients with chronic coronary artery disease (CAD, $n = 32$) and with acute coronary syndrome (ACS, $n = 32$) who were diagnosed by coronary angiography, cardiac enzyme and symptomatic findings³⁰ (Table S4). The

control group (CTRL, $n = 402$) included samples from individuals with no known history of CAD, ACS or MI and who were either healthy ($n = 125$) or had different primary diagnoses ($n = 277$) (including gum disease ($n = 25$),³⁰ breast cancer ($n = 57$),³¹ myasthenia gravis ($n = 129$), multiple sclerosis ($n = 20$),³² narcolepsy ($n = 16$),³³ or schizophrenia ($n = 30$)).

To examine confounding of age and gender, matched subgroups were generated from Estonia II and Finland I cohorts using R package “MatchIt”. Estonia II sex and age matched subgroups for CTRL and MI included age and gender matched males from *No vaccine* group (*No vaccine-M-CTRL* ($n = 13$), *No vaccine-M-MI* ($n = 18$)), and females (*No vaccine-F-CTRL* ($n = 8$), *No vaccine-F-MI* ($n = 12$)) (Table S5). Also, age and gender matched males from OPV group were included (*OPV-M-CTRL* ($n = 18$), *OPV-M-MI* ($n = 10$)) as there were no females in OPV-MI group (Table S5). For Finland I, *M-CTRL* ($n = 50$), *M-CVD* ($n = 50$), *F-CTRL* ($n = 56$), and *F-CVD* ($n = 14$) subgroups were generated (Table S6).

Mimotope-variation analysis

All study samples were analysed using the mimotope-variation analysis method (MVA,^{32,33}). In brief, modified random 12-mer peptide phage library (originally derived from Ph.D.-12, New England Biolabs) was amplified according to the manufacturer’s protocol. $2\ \mu\text{l}$ of plasma/serum samples, previously precleared to plastic and *E. coli*/wt M13 phage particles, were incubated with $2.5\ \mu\text{l}$ library ($\sim 5 \times 10^{11}$ phage particles) and immunoglobulin G (IgG) fraction was recovered using protein G-coated magnetic beads (S1430S, New England Biolabs). IgG-bound phage DNA was analysed by next generation sequencing (Illumina HiSeq, 50-bp single end reads). Sequence data were screened for sequencing errors and known artefacts, yielding specific peptide datasets for further analysis. A brief description of MVA method is provided in Figure S3.

Data processing and motif clustering

Data processing was performed as described previously.^{32,33} Final dataset consisted of 1.3×10^6 unique peptides across Estonia I discovery cohort

samples. For further analysis, we selected peptides by the criteria that a peptide was to be present in at least 10% of the samples in the study group and detected at least 10 times in one sample. For sequence-based peptide analysis and hypergeometric tests, SPEXS2 algorithm was used (<http://egonelbre.github.io/spexs2/>) with the following criteria: hypergeometric p-value $< 10^{-5}$; motif present in ≥ 4 distinct peptides; ≥ 4 fixed amino acid positions. As a result, 3260 and 759 distinct epitopes were identified for HC and MI groups, respectively. As some of the epitopes observed in HC and MI groups were identical, 3711 unique epitope consensus sequences were found altogether.

Data analysis and statistical methods

Fisher scores for unique 3711 epitope consensus sequences were calculated to find HC and MI group-differentiating epitopes (threshold > 0.04). For further analysis, 202 the most characteristic group-differentiating epitopes were selected. Epitope-forming clusters were defined using Pearson correlation matrix analysis with hierarchical clustering of peptides based on log₁₀ abundance values. Visualisation of Pearson correlation matrix was performed using R statistical programming in RStudio environment using “pheatmap” package.³⁴ To define characteristic sequence logos for each cluster, position weight matrices were generated and visualised as sequence logos using in-house “MotifTree” algorithm.³⁵

Pairwise comparisons with Mann-Whitney U test were performed for discovering the difference in antibody response to the peptides of epitopes between analysed groups. All comparisons made are indicated in the figures with brackets between respective groups. In the cases of multiple comparisons, p.adjust function in R was used to adjust p-values using Holm-Bonferroni correction. Boxplots were used to display variation in samples for tested groups and statistical results. Each boxplot indicates the median (*bold line*), 25th and 75th percentiles (*lower and upper lines* of the box), the upper whisker of the boxplots extends from upper line of the box to the largest value no further than $1.5 \times$ interquartile range (IQR, the distance between the 25th and 75th percentiles), the lower whisker extends from the lower line of the box to the smallest value at most $1.5 \times$ IQR. Boxplots were created using “ggpubr”³⁶ package in RStudio environment. y-axis of boxplots represents total abundance of peptides meaning the sum of decimal logarithms of the peptide sequence counts detected in one individual sample.

For selecting the group-differentiating peptides contributing to the 51 epitopes with G-I-X-D consensus sequence, Fisher scores were calculated (threshold > 0.03), resulting in 140 unique peptides (TOP140). TOP140 peptide abundance values were used in heatmap image analyses for the visualisation of differences in the antibody response between tested groups.

Heatmap image analyses were visualised using “pheatmap”³⁴ package in RStudio environment.

Kendall correlation analysis was performed for studying correlations between MVA and ELISA or dot ELISA results and Spearman correlation analysis for studying correlations between age and the strength of antibody response to the G-I-X-D epitope. “ggpubr”³⁶ package in RStudio environment was used to visualise correlation analyses.

For the initial G-I-X-D epitope identification, IEDB database was used (v3.0, date accessed: 24.03.2021). Since IEDB search engine does not allow searches with undetermined amino acids in the query sequences the peptide sequence G-I-E-D-L was used. The undefined amino acid in G-I-X-D was assigned as glutamic acid (E) based on observational data of amino acids in the peptides contributing to G-I-X-D. Leucine (L) was added to the 4 amino acid motif-based on observational data of amino acids in the peptides contributing to G-I-X-D to lengthen the motif and garner more substantial and specific results.

To study the origin of G-I-X-D epitope more precisely, peptides characterising Cluster I, II, and III, were selected by Fisher score analysis (TOP258, threshold > 0.03). Alignments of TOP258 peptides were performed against 100 amino acid fragments of picornaviruses (Table S2) using standalone BLAST (v. 2.8.1). Alignments were performed using “blastp-short” task³⁷ which is optimised for query sequences shorter than 30 residues (Scoring matrix: PAM30). The t-distributed Stochastic neighbor Embedding (t-SNE) analysis was performed for the visualisation of the alignment results as plots using the “Rtsne” package in R.³⁸

To assess biomarker performance on predicting MI diagnosis, receiver operating characteristic (ROC) analysis was performed on Estonia I cohort ($n = 100$; Table 1). Generalised linear model-based statistical analysis was performed with “glm” function using gaussian distribution and identity link, and visualised with “jtools” package, statistical comparison of different models was done using “anova” function with F-test in R. Also, packages “ggplot2” and “tidyverse”³⁹ in RStudio environment were used for data manipulation and visualisation.

For age and sex-matched cohort design, the age and sex of study subjects were fixed at the time of sample collection considering that MI samples were collected < 12 h before or after angiography procedures. Finland I cohort CVD samples were collected as in.²⁹

Phage dot ELISA

M13 phage particles displaying the relevant peptides were printed onto nitrocellulose coated glass slides (10,485,323, Whatman) using SpotBot® 4 arrayer (Arrayit) in four dilutions (1:2, 1:10, 1:100, 1:1000). 1xPBS-20% glycerol and mQ were used as negative controls and human IgG serial dilutions (12–50 ng/μl) as

positive controls. Human serum or plasma (1:50), previously precleared to plastic and *E. coli*/wild type M13 phage antigens, was used as primary antibody while rabbit anti-human IgG H&L (HRP) (#ab6759, Abcam, RRID: AB_955,434) (1:1000) was used as a secondary antibody. Both antibody incubations were conducted at room temperature for 1 h with agitation. The presence of bound human IgG antibodies was detected using reaction with catalyzed Signal Amplification (CSA) System II, Biotin-Free, HRP, DAB+ (Dako, Agilent, Cat#: K1497), diluted in the substrate buffer (1:100). Results were visualised using Ettan DigelMager (GE Healthcare Life Sciences) and signals (image colour-intensities) quantified using ImageQuant software version 8.1 (GE Healthcare Life Sciences).

Human coxsackievirus IgG ELISA

Anti-coxsackievirus B1, B3 and B5 VP1 epitopes serostatus was measured from 14 (7 HC and 7 MI patients) serum or plasma samples. In brief, serological analyses were performed with anti-coxsackievirus IgG ELISA method (ESR134G, SERION ELISA classic) in duplicates according to manufacturer's protocol. Absorbance was measured using SpectraMax Paradigm microplate reader (Molecular Devices). The results were interpreted according to manufacturer's specifications.

Role of funding source

We confirm no role of funders in study design, data collection, analysis and interpretation, or writing the report. The corresponding author had full access to all the data of this study and submitted the manuscript for publication.

Results

Characterisation of the top antibody response in MI patients

In order to explore antibody epitope features associated with MI, we generated immunoprofiles of the myocardial infarction patients (MI; $n = 50$) and healthy donors (HC; $n = 50$) constituting the discovery cohort Estonia I (Table 1, Figure S1 and Table S1) using the next generation peptide phage display MVA technology^{32,33} (Figure S3). In brief, individual plasma or serum samples were incubated with M13 phage-displayed 12-mer random peptide library to capture individual-specific antibody (IgG) repertoires. The DNA of IgG-bound phages was lysed and antigen coding-sequences were amplified using PCR. Then, amplicons were subjected to high-throughput DNA sequencing and the obtained data was translated to peptides underlying the subject- and group-specific immunoprofiles. For delineating antigen recognition patterns, peptides were clustered by using unsupervised hierarchical clustering analysis yielding

ultimately in 3711 consensus epitopes. From these, 202 that discriminated the healthy donors from MI patients were selected with the cut-off Fisher score values > 0.04 . Further Pearson correlation analysis revealed that 75 of the healthy group-specific epitopes (TOP75) formed three distinct clusters: Cluster I, II and III (Figure 1a). Cluster I comprised of peptides with G-I-X-D consensus, Cluster II of peptides containing W-W-N, and Cluster III of peptides containing [AS]-X-Y-X-[YF]-X-X-K consensus patterns (Figure 1b). Notably, higher antibody response to peptides containing the G-I-X-D pattern was specific for healthy people ($p = 1.5e-10$; Figure 1b), regardless of gender (Figures 1c and S4). Together, we observed a strong and homogenous antibody response to a few epitopes that was characteristic to healthy and absent or weak in patients with MI ($p = 1e-06$ for Cluster II, $p = 6.6e-06$ for Cluster III; Figure 1b). By assessing the G-I-X-D performance on Estonia I cohort ($n = 100$) as a biomarker in predicting MI using receiver operating characteristic (ROC) analysis, we found that measuring antibody response to a single (G-I-X-D) epitope as a biomarker could discriminate MI patients from healthy controls with 64% sensitivity at 84% specificity (AUC 0.740, CI 0.643 to 0.823, $p < 0.0001$; Figure S5).

Conserved epitope harbours the N-terminal G-I-X-D core structure

Since we observed a strong and rather homogenous antibody response to a few antigenic epitopes that was characteristic to healthy individuals and absent or weak in patients with MI, we analytically validated the MVA findings of the immunogenicity of the biggest G-I-X-D-defined cluster (Cluster I, Figure 1a,b) using phage dot ELISA method (Figures 2a and S6). All TOP140 G-I-X-D epitope containing peptides encompassed G-I-X-D motif N-terminally. Therefore, to examine the importance of G-I-X-D epitope location in the peptide sequence, we analysed phages displaying peptides where G-I-X-D was located either in the N-terminus (GIEDVMDVMPMP; Figure 2a) in reference to peptides or the epitope sequence was located further downstream from the N-terminus (ADGPGGPGIPDG; Figure S6). Based on MVA data, samples with either high immunoreactivity to TOP140 peptides containing the G-I-X-D epitope (abundance values > 40 ; HC, $nr1-5$ and MI, $nr1,2$) or low immunoreactivity (abundance values < 25 ; HC, $nr6,7$ and MI, $nr3-7$) from Estonia I cohort (Table S1) were selected for analysis. Phage dot ELISA analysis data confirmed the MVA data findings on the antibody reactivity to the G-I-X-D epitope (Figure 2a), but also established that N-terminal location of the epitope was imperative to discriminate between samples with high and low immunoreactivity (Kendall correlation, $R = 0.6$, $p = 0.002$; Figure 2b). Altogether, these analyses confirm that N-terminal G-I-X-D is a highly immunogenic




Figure 1. MVA analysis reveals three major epitopes associated with a differential antibody response in MI diseased compared to healthy controls. **a.** Clustering of peptides of the Estonia I cohort resulted altogether in 3711 unique epitope patterns. Fisher score (threshold >0.04) was used to select the most group-differentiating ones, resulting in 202 epitopes. Using Pearson correlation matrix analysis and hierarchical clustering based on log₁₀ abundance, TOP75 epitope patterns clustered into 3 group-differentiating epitopes (Clusters I, II and III). Dark blue colour shows high correlation between TOP75 epitopes (>0.7), light blue - low correlation (<0.3). **b.** The immunoreactivity to the 3 group-differentiating epitopes discriminates between HC and subjects with MI. On boxplots, *bold line* indicates the median, *lower and upper lines* indicate 25th and 75th percentiles, and *whiskers* are shown in the style of Tukey. Pair-wise comparison with Mann-Whitney U test, *p-values* reported above the brackets. Sequence logos (on the right) of G-I-X-D for Cluster I, W-W-N for Cluster II, and [AS]-X-Y-X-[YF]-X-X-K for Cluster III. *y axes* - Abundance, IgG bound peptides, anti-G-I-X-D seroresponse measured by MVA. **c.** Heatmap image analysis of TOP140 peptides from Cluster I shows that antibody response to this epitope is more common in healthy individuals. Each column represents the TOP140 peptide profile of the individual sample. Each line represents a peptide with unique sequence. Colour code (Abundance in log₁₀) depicts the strength of immunoreactivity to unique peptides in rows containing the G-I-X-D epitope. HC – healthy controls; MI – myocardial infarction patients.




Figure 2. Phage dot ELISA data confirms MVA findings linking immune response to G-I-X-D core epitope with improved cardiac health. a. Seven samples from both, HC and MI groups were selected for phage dot ELISA assay based on high (HC1–5, MI1,2) or low seroreponse (HC6,7, MI3–7) to TOP140 peptides containing the G-I-X-D epitope. N-terminally G-I-X-D epitope displaying phages (GIEDVMDVMPMP) along with FLAG epitope (DYKDDDDK) displaying phages as negative controls (*Control*) were incubated with selected serum or plasma samples. Results are shown as relative (%) to the highest detected signal across study samples (*y*-axis). Error bars indicate SEM ($n = 2$ technical replicates). b. Phage dot ELISA and MVA data of selected samples are in strong positive correlation (Kendall correlation, $R = 0.6$, $p = 0.002$), whereas in moderate correlation with coxsackie viral antigens (Fig. S8a). HC – healthy controls; MI – myocardial infarction patients.

epitope detected in antibody immune response profiles of healthy subjects of Estonia I cohort.

Conservation of the antibody G-I-X-D epitopes across the enteroviral species

We next used the immunoprofile data collected from the Estonia I cohort to look for possible associations of the defined motifs with pathogen-associated antigens. Substring searches of the Immune Epitope Database and Analysis Resources (IEDB, date accessed: 24.03.2021; www.iedb.org) using linear peptides with “GIEDL” sequence that contribute substantially to the harbored G-I-X-D epitope were performed. This resulted in two referenced epitopes with sequences of GIEDLISEVAQGALTSL (ID 79,229,⁴⁰) and GIEDLISEVAQGAL (ID 100,065,⁴¹), respectively, that both were derived of the genome polyprotein of EV-C (human poliovirus type 3). Next, to widen the pool of potential pathogens, substring searches with shorter “GI” sequence across Enteroviruses (ID 12,059, Enterovirus) resulted in 30 records. Data showed that PVs, coxsackieviruses A (CV-A) and coxsackieviruses B (CV-B) all share high sequence similarity encompassing amino acids 1 to 11 downstream of the VP3/VP1-specific protease 3C cleavage site (Figure 3a and Table S2). Further alignment analysis of peptides from Clusters I, II, and III differentiating the HC group of Estonia I (Figure 3b and Table S2) confirmed that Cluster I defined by the

G-I-X-D consensus epitope was highly specific to the N-terminus of EV-C VP1 antigens (Figure 3c). Notably, the N-termini of VP1 proteins of the human poliovirus type 3 (PV3), coxsackieviruses A17 (CA17) and A20 (CA20) showed the highest homology with G-I-X-D-containing peptides, whereas peptides of Clusters II and III did not align to EV-C proteomes (Figure 3b). Next, we investigated whether the G-I-X-D epitope could originate from other picornaviral species. Data showed that in addition to EV-C, G-I-X-D core epitope-containing peptides aligned also to different species of EV-A, EV-B and parechovirus A types (Figure 3c and Table S2). In addition, high similarity was observed with VP1 N-termini of vaccine-derived polioviruses (VDPVs), namely VDPV3 (VDPV3/EST/Env2008 (GenBank: KC784372.1, Figure 3a). Of note, analysing our MVA data we found that seroreactivity to the recently described peptide sequences PALTAVETG and PALTAAETG, derived of the VP1 proteins of human PV-1/3 and CV-B1/B3 viruses and also shared by many other picornaviruses,⁴² did not differentiate MI cases from controls (Figure S7), further confirming the functional relevance of the G-I-X-D findings. Then, we used conventional ELISA method to measure IgG response in Estonia I cohort sera ($n = 14$; same samples as in Figure 2a) against VP1 of several enteroviral species, including coxsackieviruses B1, B3 and B5 and with reported cross-reactivity to poliovirus type 3.⁴³ Interestingly, differential readouts were obtained for all samples analysed and there was a




Figure 3. N-terminal G-I-X-D sequence is common in picornaviral VP1 proteins. a. Alignments of N-termini of VP1 sequences of poliovirus (PV) and non-PV species (Table S2) are shown. Scissors indicate PV3/PV1 protease 3C cleavage sites in PVs, VDPVs and coxsackieviruses A and B. Colours indicate >40% amino acid identities in select positions (different colours indicate different amino acids). b,c. TOP258 peptides with epitopes of Cluster I, II and III were aligned to 100 aa fragments of select enteroviral C (b) and other picornaviral proteomes (c) (Table S2) using standalone BLAST. Interrupted lines indicate peptide affiliation to the cluster (pink-coloured line – Cluster I, blue-coloured line – Cluster II, green-coloured line – Cluster III). The dot indicates one alignment with each of the TOP258 peptides. Peptides with no alignments or peptides aligned to one region only are shown as one dot, peptides aligned to many fragments are shown as repeated dots according to the number of alignments. The size of each dot corresponds to peptide abundance (Counts) across the HC cohort. Viruses are colour coded. VDPV – vaccine-derived poliovirus; PV1, PV2, PV3 – poliovirus 1, 2, or 3, respectively; CA1, CA11, CA13, CA17, CA19, CA20, CA21, CA22, CA24, CB1, CB2, CB3, CB4, CB5, CB6 – coxsackievirus A1, A11, A13, A17, A19, A20, A21, A22, A24, B1, B2, B3, B4, B5, or B6, respectively; NI – peptides with no alignments to the picornaviruses (grey dots); y- and x-axes: tsne1, 2, or 3 – t-SNE dimension 1, 2, or 3, respectively.

moderate linear relationship with MVA G-I-X-D findings (Kendall correlation, $R = 0.35$, $p = 0.079$; Figure S8a). However, only a few ($n = 3$) serum samples exceeded the thresholds for coxsackieviral IgG seropositivity (Figure S8b). Overall, from this data it can be concluded that the

antibody response to G-I-X-D epitopes could stem from the PVs and/or PV vaccine antigens, also from vaccine-derived polioviruses (VDPVs) and/or from alike viral antigens, such of VP1 of EV-B types (coxsackieviruses B), but also other species of picornavirus family.

Immunoreactivity to G-I-X-D epitope is associated with OPV/IPV use and is weak in patients with myocardial infarction

We hypothesised that the observed differences in seroreactivity patterns to G-I-X-D could be associated with PV immunisation (Figure S2). To investigate this hypothesis, we created the second stage of the study with the second Estonian discovery cohort (Estonia II, Figure S1) that included samples of individuals ($n = 329$) that were grouped according to the year of birth. People born before the year 1959 when no vaccination with OPV against PV was available in Estonia comprised group *No vaccine* ($n = 101$) (Figure 4 and Table S3). Individuals born in the years of OPV vaccination in Estonia, 1959–2007, comprised group *OPV* ($n = 224$) and individuals born in the years of IPV vaccination, the year 2008 and later were included in *IPV* group ($n = 4$) (Figures 4 and S2 and Table S3). Data analysis concluded that high seroreactivity to the G-I-X-D epitope was common to the *OPV* group and was low in *No vaccine* and *IPV* groups (Mann Whitney U test, $p < 0.0001$ or $p < 0.05$, respectively, Holm-Bonferroni adjustment for 3 comparisons) (Figure 4a,b). No gender differences in any vaccine groups were detected (Figures 4a and S9). Additionally, individuals without a history of MI from Estonia II cohort ($n = 309$) in the *OPV* group showed higher seroreactivity to the G-I-X-D epitope as compared with individuals from *No vaccine* and *IPV* groups (Mann Whitney U test, $p < 0.001$ or $p < 0.05$, respectively, Holm-Bonferroni adjustment for 3 comparisons) (Figure S10). However, no correlation between the antibody response to the G-I-X-D epitope and the age of the subjects within the *OPV* group was found (Spearman correlation, $R = 0.071$, $p = 0.3$; Figure S11). We further used statistical modelling of data to determine whether vaccination status, age and gender affect antibody response to G-I-X-D epitope, and found that in contrast to OPV vaccination, gender and age had no significant effects on the seroresponse to G-I-X-D epitope (Table S7). Adding an interaction term between age and gender failed to improve the model (F-test, $p = 0.5092$). Therefore, we concluded that the antibody response to G-I-X-D epitope did not depend on gender or age, but only on OPV vaccination and MI diagnosis.

Next, we analysed the Estonia I cohort to evaluate association of the immunoreactivity to G-I-X-D with the risk of MI independent of the poliovirus vaccine exposure. Importantly, patients with MI exhibited a significant decrease in immune response to the G-I-X-D epitope compared to healthy individuals of *No vaccine* and *OPV* groups (Mann Whitney U test, $p < 0.05$, Holm-Bonferroni adjustment for 4 comparisons) (Figure 4c). Moreover, analysis of subgroups of the Estonia II cohorts matched by the vaccination status, age and gender (Table S5) further confirmed the findings that patients with MI showed significantly reduced

response to G-I-X-D epitope compared to people without primary diagnosis of MI (Figure S12).

Next, to replicate findings of the G-I-X-D epitope association with cardiovascular disease and poliovirus vaccines, we comparatively analysed the data from the immunoprofiles of Finland I validation cohort ($n = 466$) (Figure S1, Table S4). IPV has been the predominantly used vaccine by the Finnish national poliovirus immunisation programme, apart from years 1984–1985 with high rate of OPV use (<https://www.cdc.gov/mmwr/preview/mmwrhtml/00000682.htm>). Data analysis showed that antibodies against G-I-X-D epitopes were more prevalent in healthy subjects of Estonia I cohort than in the control subjects of Finland I cohort ($p < 0.0001$, Holm-Bonferroni adjustment for 4 comparisons, Figure 4d). However, the anti-G-I-X-D antibody response was significantly lower in CVD (MI or CAD/ACS) subgroup as compared to controls of both Estonia I and Finland I (Mann Whitney U test, $p < 0.0001$ and $p < 0.001$, respectively, Holm-Bonferroni adjustment for 4 comparisons, Figures 4d and S13 (CTRL vs ACS)). A weak negative correlation between age and the anti-G-I-X-D seroresponse (Spearman correlation, $R = -0.14$, $p = 0.0041$) in the Finland I control group ($n = 402$) was observed (Figure S14). Therefore, we excluded the effects of age on the observed association between the increased risk of CVD and decreased antibody response to the G-I-X-D epitope. Analysing the age and sex-matched subgroup of the Finland I cohort (Table S6), we found that anti-G-I-X-D antibody response was significantly lower in men with CVD compared to controls (Mann Whitney U test, $p < 0.05$, Holm-Bonferroni adjustment for 2 comparisons), whereas no statistically significant effect was seen for women (Mann Whitney U test, $p = 0.83$, Holm-Bonferroni adjustment for 2 comparisons), possibly due to the small sample size for this gender group (Figure S15).

Finally, we used generalised linear model-based statistical modelling across our cohorts (Estonia II, and Finland I) to determine the relationship between the anti-G-I-X-D seroresponse and CVD, taking into account the vaccination status, age and gender (Figure 4e, Table S8). Our results indicated that vaccination with OPV was strongly associated with an increased anti-G-I-X-D seroreactivity in both men and women (34% and 29%, respectively), whereas vaccination with IPV and increasing age of patients showed slight decreasing but statistically insignificant trends in the anti-G-I-X-D seroresponse. Importantly, the modelling across all data showed that CVD diagnosis was associated with 36% and 24% drop in the anti-G-I-X-D seroresponse in both men and women, respectively (Figure 4e, Table S8).

Altogether, our data conclude that a low titer antibody response to the G-I-X-D epitope is associated with cardiac complications. Our results additionally suggest beneficial effects of polio vaccinations with OPV even in countries that have eradicated poliovirus.




Figure 4. High immunoreactivity to the G-I-X-D epitope is associated with improved cardiac health. **a.** MVA data of subjects from Estonia II cohort with the known year of birth independent of their diagnosis were selected to analyse the association of the antibody reactivity to G-I-X-D epitope with polio vaccinations (Fig. S2). Regarding clinical background, the Estonia II cohort consisted of MI cases ($n = 40$) and either healthy blood donors (ICD-10: Z52.0, $n = 135$) or samples from individuals with different primary diagnoses with no history of MI ($n = 154$). All individuals were grouped according to their year of birth, forming three major groups as follows: *No vaccine* ($n = 101$; people born before 1959, years when no vaccination against poliomyelitis was done in Estonia), *OPV* ($n = 224$; individuals born in years 1959–2007 when OPV vaccination in Estonia was in the national immunisation schedule), *IPV* ($n = 4$; individuals born in 2008 and after, years of IPV vaccination in Estonia). Heatmap shows the antibody response to TOP140 peptides containing the G-I-X-D epitope. Each column represents the TOP140 peptide immunoprofiles in individual samples. Each line represents a peptide with unique sequence. Intensity of the colour correlates with the strength of immunoreactivity to the G-I-X-D peptides in rows (*Abundance*, in log₁₀). **b.** People born in years of OPV vaccination in Estonia (1959–2007, *OPV*) have higher immunoreactivity to G-I-X-D peptides as compared with *No vaccine* or *IPV* groups. Groups: *No vaccine* ($n = 101$); *OPV* ($n = 224$) and *IPV* ($n = 4$), the entire Estonia II cohort, including MI cases (Table S3). **c.** High immunoreactivity to peptides with G-I-X-D detected in healthy individuals born in Estonia in years of OPV vaccination (1959–2007, *HC-OPV*) as well as in those born before 1959 (*HC-No vaccine*) as compared to low antibody response observed in MI patients (*MI-No vaccine* and *MI-OPV*). Groups: *HC-No vaccine* ($n = 7$); *HC-OPV* ($n = 43$); *MI-No vaccine* ($n = 30$); *MI-OPV* ($n = 10$). **d.** High immune reactivity to G-I-X-D epitope observed in subjects of

Discussion

Herein we identified a highly antigenic epitope located at the N-terminus of VP1 proteins of EV-B and -C type enteroviruses (EVs), including polioviruses (PVs), and observed that strong antibody immune response to this epitope was associated with improved cardiovascular health. Thus, this epitope has the potential as a site of broadly neutralising reactivity against EVs and possibly other species of the picornavirus family. Secondly, the conserved G-I-X-D epitope has potential as blood biomarker for risk assessments of major cardiac events, as poor response against the conserved G-I-X-D epitope was strongly associated with severe cardiac conditions of MI and CAD/ACS. Still, the mechanisms by which inadequate antibody response to the G-I-X-D epitope contributes to the progression of MI need further studies. Lastly, our data highlight the potential beneficial role of heterologous cross-reactive immunity of PV vaccines or natural EV infections against a spectrum of clinical heart conditions.

Exploratory data analysis of this study using MVA identified an epitope mimicking the N-terminus of VP1 protein of EV-C type and alike viral species that was strongly associated with improved cardiac health (Figure 1). Namely, poor antibody response to this epitope with G-I-X-D consensus stratified MI subjects from healthy with 64% sensitivity at 84% specificity (Figure S5). Further analytical validation and annotation analyses concluded that the major antigenic site (the N-terminal glycine of the processed VP1 viral antigen) is highly conserved across EVs, in particular among the EV-B and EV-C species, also in PVs and VDPVs, and additionally among other *Picornaviridae* (Figure 3c). Comparative conventional ELISA testing for enteroviral anti-VP1 seroresponse showed limited concordance with MVA findings, further supporting the wider viral origin of the G-I-X-D epitope. These data have global implications. The genus *Enterovirus* includes rhinoviruses and EVs (types A to D, with EV-C including PVs 1 to 3) that infect humans.⁴⁴ The climate and socio-economic factors contribute to the geographic distribution of different EV types.^{44,45} In Europe and the United States, for example, EVs are found in 5–12% of the population.⁴⁶ Most of

these belong to EV-B, whereas in Asia, EV-A types are common.^{47–49} In contrast, non-polio type EV-Cs are relatively rare.⁴⁵ Notably, EV genotypes change over time primarily through recombination of both conventional and unconventional EV types that most frequently occurs at non-capsid regions, as reported for EV-As.⁵⁰ Viruses constituting the oral poliovirus vaccine (OPV) are inherently genetically instable.^{51,52} Recombination with other EV-C types into highly divergent strains⁴⁶ leads to the OPV-derived VDPVs that achieve the level of transmissibility similar to natural PVs^{53–55} and can cause acute flaccid paralysis.⁵⁶ It is well documented that following persistent EV infections, cardiac tissues become inflamed⁵⁷ and that EV types A and B are responsible for cardiac disease.^{58,59} In this study, we show that the G-I-X-D epitope is well-conserved across EVs and even wider across other species of *Picornaviridae*, suggesting that heterologous immunity can be mediated by cross-reactive antibodies to shared antigens of this rapidly evolving virus family.

The immunoprofiling of people of Estonia II cohort born during the OPV vaccination (1959–2007) revealed that high titer antibody response against the G-I-X-D epitope was more common compared to those individuals born before 1959, when no vaccines were available (Figure 4b), and also compared to the individuals of Finland I cohort, who had mostly received IPV polio vaccine according to the Finnish national immunisation programmes (<https://www.cdc.gov/mmwr/preview/mmwrhtml/00000682.htm>) (Figure 4d,e). These differences in the observed anti-G-I-X-D response could be explained by the difference in the antigenic structure of poliovirus vaccines. Commercial IPVs are produced by incubations with formaldehyde that is known to result in some loss of immunogenicity due to the partial destruction of specific antigenic epitopes.⁶⁰ Notably, the antibody response to VP3/VP1 cleavage site of PVs has been detected in OPV but not in IPV recipients, thus leaving a gap in the PV-associated immune response.⁶¹ Most recent studies have shown high sequence variability of the VP1 N-terminal domain,⁶² that is externalised in the α -helical conformations for interactions with host cell membranes.^{63, 64} Despite the

Finland I with no CVD diagnostic history (*CTRL-FIN*) and in donors from Estonia I (*HC-EST*) as compared to individuals from groups of cardiovascular disease (*CAD/ACS*, *CVD-FIN* and *MI*, *MI-EST*, correspondingly). Groups: *HC-EST* ($n = 50$) and *MI-EST* ($n = 50$) – Estonia I discovery cohort (Table 1); *CTRL-FIN* ($n = 402$) and *CVD-FIN* ($n = 64$) – Finland I cohort (Table S4). b–d. Pairwise comparison with Mann-Whitney U test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, Holm-Bonferroni correction was used to adjust p -values for multiple comparisons. On boxplots, **bold line** indicates the median, *lower* and *upper lines* indicate 25th and 75th percentiles, and *whiskers* are shown in the style of Tukey. *y axes* – *Abundance*, *IgG bound peptides*, anti-G-I-X-D seroresponse measured by MVA. *HC* – healthy controls; *MI* – myocardial infarction patients; *CVD* – cardiovascular disease (including acute coronary syndrome patients (*CAD/ACS*)); *CTRL* – control group e. Modelling of anti-G-I-X-D response in Estonia II and Finland I cohorts with generalised linear model using the formula “ $\log_2(\text{G-I-X-D abundance}) \sim \text{Vaccination status} + \text{Age}/10 + \text{CVD diagnosis}$ ”. People younger than 18 years were excluded from the analysis, non-vaccinated people with no primary diagnosis of CVD were used as the reference level. Estimates of the indicated coefficients (*y-axis*) are shown with circles and squares, 95% confidence interval is shown with line. *OPV* and *IPV* indicate vaccination with the respective vaccine, *Age/10* indicates age divided by 10 (i.e., the effect of being 10 years older), *MI/CAD/ACS* designates any of the indicated primary diagnosis.

VP1 N-terminal hypervariability, the Gly residue of the Q/G dipeptide forming the VP3/VP1 cleavage site⁶⁵ that is part of the G-I-X-D epitope defined by our study, remains highly conserved.⁶⁶ Thus, the findings of the current study suggest that the data on the G-I-X-D epitope could be useful in advancing poliovirus vaccines or in testing vaccine efficacy against evolving PV strains. To the best of our knowledge, there is neither monoclonal antibody that would correlate with protective properties in humans and be used to estimate polio vaccine potency nor a validated test for the analysis of epitope-specific poliovirus-induced antibody response. This is important, given that the same widely accepted structural rearrangement model of the VP1 capsid proteins is valid across picornaviruses.⁶⁴

Here we define the role of an EV-associated common epitope as protective against acute CVD events (MI and ACS). The latter is not surprising as EVs have been detected in atherosclerotic plaques⁶⁷ and, as highlighted recently, in association with MI plaque disruptions.⁶⁸ In one study, antibody response to EV antigens was detected in 49% of patients with CAD and in 54.3% of those with MI.⁶⁹ Other studies observed that coxsackievirus B (CV-B) promoted atherosclerosis in animal models.⁷⁰ However, the mechanisms of how EVs contribute to CVDs are not clear. Based on our study data, inadequate antibody response against the N-terminus of VP1 presenting the G-I-X-D epitope could hypothetically allow direct infection and lytic effects or the poor clearance of the EV species and lead to chronic inflammation of the heart tissue. We observed that anti-G-I-X-D antibody response was relatively lower in subjects of Finland I in general as compared to Estonia I cohort and was determined as particularly low in the MI subgroup of Estonia I and CVD subgroup of Finland I (Figures 4d and S13). Based on our modelling data (Figure 4e), we suggest that these differences could be explained by the differential use of PV vaccines (OPV vs IPV) between countries, also by individual heterologous immunity towards EV/picornaviral species, both of which are essential to support cardiovascular health. Potentially, changes in the gut microbiota composition linked with CVD⁷¹ could impair gut immune regulation promoting EV replication.⁷² Our data highlight the importance of the long-term, stable, and high-titer antibody response against the N-terminal epitope of VP1 antigen of EVs in protecting against severe heart damage (MI, CAD, ACS). However, further studies are needed to establish robust correlations.

The main strengths of this study are concordant results in two ethnic populations covering a wide age range that the antibody response to a highly antigenic epitope reflects improved cardiovascular health. Additionally, the study includes a comprehensive analysis of the antibody epitope repertoire associated with enteroviruses and cardiovascular health. The main weaknesses are associated with the retrospective study design that

we complemented with a descriptive analysis of publicly available data on national immunisation programmes against polio in Estonia and in Finland (Figure S2). We describe a potential biomarker for the assessment of risks associated with severe CVD (MI and ACS) and raise important questions on the role of common viral infections in the heart pathophysiology. The exact mechanisms by which these may lead to heart failure remain to be established. Our results stress the importance of dissecting the role of heterologous immunity against EV infections, also primed by globally used PV vaccines.

Contributors

NP, AA, MJ, HS, AR, AP (Arno Pihlak), and KP conceived and designed the study. AP (Anu Planken), MP, EK, MRJS, PJT, JKN, AV, DL, JS, PP and TT collected samples and acquired the clinical data. NP, AA, JT, HS, AP (Arno Pihlak), MJ, AR, and KP analysed and interpreted the data. NP, AA, JT, AP, MJ, and AR verified the data. EK, PJT, DL, PP, TT, and KP supervised the study. NP and KP drafted the manuscript. All authors had access to the data in the study. All authors revised and approved the final manuscript for submission.

Data sharing statement

The data are not publicly available due to containing information that could compromise research participant privacy/consent. Any materials that can be shared will be released via a material transfer agreement.

Declaration of interests

AP (Arno Pihlak) and KP are inventors of the patent application (PCT Application No. US/14,079,626) filed by Protobios that covers the use of phage display method for manipulating and monitoring humoral immunity. NP, HS, AP (Arno Pihlak), MJ, JT, AR, TT, and KP are affiliated with Protobios Llc. JS reported payment/honoraria from Astra-Zeneca, Amgen, Abbott and Bayer. All other authors declare no competing interests.

Acknowledgments

We thank A.-H. Pool, Department of Neuroscience, University of Texas Southwestern Medical center, for his expertise that supported this work. The members of Protobios team are thanked for their excellent technical assistance. This study was supported by institutional research funding grants of Protobios (5.1-4/20/170, and PRG573) from the Estonian Ministry of Education and Estonian Research Council, respectively, and H2020-MSCA-RISE-2016 (EU734791) and H2020 PANBioRA (EU760921) projects from the European Union, Helsinki University Hospital grants, Mary and Georg C.

Ehrnrooth Foundation, and Finnish Eye Foundation. AA, MP and TT were partially supported by Estonian Research Council (grant PRG805) and European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012). DL was supported by Finska Läkaresällskapet and The Finnish Society of Sciences and Letters. AV was supported by Magnus Ehrnrooth Foundation and Sigrid Jusélius Foundation. JT was partially supported by the grant from Estonian Ministry of Education and Research (2014-2020.4.01.21-0315).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.ebiom.2022.103835](https://doi.org/10.1016/j.ebiom.2022.103835).

References

- Roth GA, Mensah GA, CO Johnson, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76(25):2982-3021.
- Timmis A. European heart journal - quality of care & clinical outcomes: becoming the go-to journal for cardiovascular outcomes research worldwide. *Eur Heart J*. 2019;40(46):3753.
- Michalak M, Agellon LB. Stress coping strategies in the heart: an integrated view. *Front Cardiovasc Med*. 2018;5:168.
- Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. *Nat Rev Cardiol*. 2020;17(1):9-21.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352(16):1685-1695.
- Ross R. Atherosclerosis is an inflammatory disease. *Am Heart J*. 1999;138(5 Pt 2):S419-S420.
- Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. *Thromb Haemost*. 2011;106(5):858-867.
- Murillo H, Restrepo CS, Marmol-Velez JA, et al. Infectious diseases of the heart: pathophysiology, clinical and imaging overview. *Radiographics*. 2016;36(4):963-983.
- Sato K, Sinclair JE, Sadeghirad H, Fraser JF, Short KR, Kulasinghe A. Cardiovascular disease in SARS-CoV-2 infection. *Clin Transl Immunol*. 2021;10(9):e1343.
- Szwed P, Gasecka A, Zawadka M, et al. Infections as novel risk factors of atherosclerotic cardiovascular diseases: pathophysiological links and therapeutic implications. *J Clin Med*. 2021;10(12):2539.
- Mitra S, Drautz-Moses DI, Alhede M, et al. In silico analyses of metagenomes from human atherosclerotic plaque samples. *Microbiome*. 2015;3:38.
- Pothineni NVK, Subramany S, Kuriakose K, et al. Infections, atherosclerosis, and coronary heart disease. *Eur Heart J*. 2017;38(43):3195-3201.
- Patel P, Mendall MA, Carrington D, et al. Association of helicobacter pylori and chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. *BMJ*. 1995;311(7007):711-714.
- Pussinen PJ, Jousilahti P, Alfhthan G, Palosuo T, Asikainen S, Salomaa V. Antibodies to periodontal pathogens are associated with coronary heart disease. *Arterioscler Thromb Vasc Biol*. 2003;23(7):1250-1254.
- Reunanen A, Roivainen M, Kleemola M, et al. Enterovirus, mycoplasma and other infections as predictors for myocardial infarction. *J Intern Med*. 2002;252(5):421-429.
- Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. *Circulation*. 2000;101(3):252-257.
- Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. *Stroke*. 2002;33(11):2581-2586.
- Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. *Circulation*. 2001;104(1):25-31.
- Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. *Am J Cardiol*. 2000;85(2):140-146.
- Pesonen E, Andberg E, Ohlin H, et al. Dual role of infections as risk factors for coronary heart disease. *Atherosclerosis*. 2007;192(2):370-375.
- Burgner DP, Sabin MA, Magnussen CG, et al. Early childhood hospitalisation with infection and subclinical atherosclerosis in adulthood: the Cardiovascular Risk in Young Finns Study. *Atherosclerosis*. 2015;239(2):496-502.
- Pussinen PJ, Paju S, Koponen J, et al. Association of childhood oral infections with cardiovascular risk factors and subclinical atherosclerosis in adulthood. *JAMA Netw Open*. 2019;2(4):e192523.
- Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. *Nat Rev Drug Discov*. 2021;20(8):589-610.
- Lawson JS. Multiple infectious agents and the origins of atherosclerotic coronary artery disease. *Front Cardiovasc Med*. 2016;3:30.
- Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *N Engl J Med*. 2019;380(2):171-176.
- Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. *Eur Respir J*. 2018;51(3):1701794.
- Chumakov MP. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. *Bull World Health Organ*. 1961;25:79-91.
- Horstmann DM. The Sabin live poliovirus vaccination trials in the USSR, 1959. *Yale J Biol Med*. 1991;64(5):499-512.
- Vaara S, Nieminen MS, Lokki ML, et al. Cohort profile: the Corogene study. *Int J Epidemiol*. 2012;41(5):1265-1271.
- Liljestrand JM, Paju S, Pietiainen M, et al. Immunologic burden links periodontitis to acute coronary syndrome. *Atherosclerosis*. 2018;268:177-184.
- Mustonen L, Aho T, Harno H, Sipila R, Meretoja T, Kalso E. What makes surgical nerve injury painful? A 4-year to 9-year follow-up of patients with intercostobrachial nerve resection in women treated for breast cancer. *Pain*. 2019;160(1):246-256.
- Sadam H, Pihlak A, Jaago M, et al. Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients. *EBioMedicine*. 2021;64:103211.
- Sadam H, Pihlak A, Kivil A, et al. Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling. *EBioMedicine*. 2018;29:47-59.
- Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2021 Apr 21]. Available from: <https://CRAN.R-project.org/package=pheatmap>.
- Krupp M. Finding motifs from short peptides [Internet]. 2013 [cited 2021 Jun 11]. Available from: <https://conserv.cs.ut.ee/home/files/Mari-Liis+Kruup+-+Finding+motifs+from+short+peptides.pdf?study=ATILoputoo&reference=C2F24DE244D358C55E32D7A221FEE5CB523D4E9C>.
- Kassambara A. ggpubr: "ggplot2" Based Publication Ready Plots [Internet]. 2020 [cited 2021 Apr 21]. Available from: <https://CRAN.R-project.org/package=ggpubr>.
- Madden T. BLAST+ features. BLAST® Command Line Applications User Manual. National Center for Biotechnology Information (US) [Internet]. 2020 [cited 2021 Oct 1]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK569839/>.
- Krithe JH. Rtsne: t-distributed stochastic neighbor embedding using a Barnes-Hut implementation [Internet]. 2015 [cited 2021 Apr 21]. Available from: <https://github.com/fkrijthe/Rtsne>.
- Wickham H, Averick M, Bryan J, Chang W, McGowan L. Welcome to the tidyverse. *J Open Source Softw*. 2019;4:43.
- Graham S, Wang EC, Jenkins O, Borysiewicz LK. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. *J Virol*. 1993;67(3):1627-1637.
- Roivainen M, Piirainen L, Rysa T, Narvanen A, Hovi T. An immunodominant N-terminal region of VP1 protein of poliovirus that is buried in crystal structure can be exposed in solution. *Virology*. 1993;195(2):762-765.
- Harb J, Mennesson N, Lepetit C, et al. Comparison of monoclonal gammopathies linked to poliovirus or coxsackievirus vs. other infectious pathogens. *Cells*. 2021;10(2):438.

- 43 Swanink CM, Veenstra L, Poort YA, Kaan JA, Galama JM. Coxsackievirus B1-based antibody-capture enzyme-linked immunosorbent assay for detection of immunoglobulin G (IgG), IgM, and IgA with broad specificity for enteroviruses. *J Clin Microbiol.* 1993;31(12):3240–3246.
- 44 Lukashev AN, Vakulenko YA. Molecular evolution of types in non-polio enteroviruses. *J Gen Virol.* 2017;98(12):2968–2981.
- 45 Brown DM, Zhang Y, Scheuermann RH. Epidemiology and sequence-based evolutionary analysis of circulating non-polio enteroviruses. *Microorganisms.* 2020;8(12):E1856.
- 46 Brouwer L, van der Sanden SMG, Calis JCJ, et al. High frequency of polio-like enterovirus C strains with differential clustering of CVA-13 and EV-C99 subgenotypes in a cohort of Malawian children. *Arch Virol.* 2018;163(10):2645–2653.
- 47 Mohamadpoor T, Nabavinia M, Gholoobi A, Alavi M, Meshkat Z. Enteroviruses in acute myocardial infarction. *Iran J Public Health.* 2012;41(8):71–74.
- 48 Roger VL. Epidemiology of myocardial infarction. *Med Clin N Am.* 2007;91(4):537–552. ix.
- 49 Shin SY, Kim KS, Lee YS, et al. Identification of enteroviruses by using monoclonal antibodies against a putative common epitope. *J Clin Microbiol.* 2003;41(7):3028–3034.
- 50 Wang M, Zhu L, Fan J, et al. Rules governing genetic exchanges among viral types from different enterovirus clusters. *J Gen Virol.* 2020;101(11):1145–1155.
- 51 Agol VI. Molecular mechanisms of poliovirus variation and evolution. *Curr Top Microbiol Immunol.* 2006;299:211–259.
- 52 Agol VI. Vaccine-derived polioviruses. *Biologicals.* 2006;34(2):103–108.
- 53 Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. *Risk Anal.* 2013;33(4):606–646.
- 54 Famulare M, Selinger C, McCarthy KA, Eckhoff PA, Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. *PLOS Biol.* 2018;16(4):e2002468.
- 55 Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. *N Engl J Med.* 2010;362(25):2360–2369.
- 56 Fernandez-Garcia MD, Kebe O, Fall AD, Ndiaye K. Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013–2014. *Sci Rep.* 2017;7(1):3808.
- 57 Bouin A, Gretteau PA, Wehbe M, et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5' terminal genomic RNA-deleted viral populations with viral-encoded proteinase activities. *Circulation.* 2019;139(20):2326–2338.
- 58 Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. *Eur Heart J.* 2008;29(17):2073–2082.
- 59 Knowlton KU. Dilated cardiomyopathy. *Circulation.* 2019;139(20):2339–2341.
- 60 Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of formaldehyde inactivation on poliovirus. *J Virol.* 2014;88(20):11955–11964.
- 61 Herremans T, Reimerink JH, Kimman TG, van Der Avoort HG, Koopmans MP. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. *Clin Diagn Lab Immunol.* 2000;7(1):40–44.
- 62 Shah PNM, Filman DJ, Karunatilaka KS, et al. Cryo-EM structures reveal two distinct conformational states in a picornavirus cell entry intermediate. *PLOS Pathog.* 2020;16(9):e1008920.
- 63 Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol.* 2021;18(3):169–193.
- 64 Jimenez-Clavero MA, Escibano-Romero E, Douglas AJ, Ley V. The N-terminal region of the VP1 protein of swine vesicular disease virus contains a neutralization site that arises upon cell attachment and is involved in viral entry. *J Virol.* 2001;75(2):1044–1047.
- 65 Xia X, Xie Z. Protein structure, neighbor effect, and a new index of amino acid dissimilarities. *Mol Biol Evol.* 2002;19(1):58–67.
- 66 Shaw J, Jorba J, Zhao K, et al. Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak. *J Virol.* 2018;92(9):e01949–17.
- 67 Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. *Arch Med Res.* 2015;46(5):339–350.
- 68 Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *Reply N Engl J Med.* 2019;380(15):e21.
- 69 Plotkin V, Voronel VL, Timoshina MA, Zaripova ZA, Murina EA, Khromov-Borisov NN. Enterovirus infection as a risk factor of acute coronary syndrome and its complications. *Klin Med (Mosk).* 2011;89(2):25–29.
- 70 Ilback NG, Mohammed A, Fohlman J, Friman G. Cardiovascular lipid accumulation with Coxsackie B virus infection in mice. *Am J Pathol.* 1990;136(1):159–167.
- 71 Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. *Proc Natl Acad Sci USA.* 2011;108(Suppl 1):4592–4598.
- 72 Kuss SK, Best GT, Etheredge CA, et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. *Science.* 2011;334(6053):249–252.